The Denmark-based biotech company, Novo Nordisk A/S (NVO), is trading 4% lower in the market despite the company posting no corporate-related news to affect the stock. The stock continued to drop in the past 20 days, losing 10% since December 16, 2021. The stock is currently dealing at $104.77, down $4.02 or 3.70% since the previous close at $108.79. The stock opened at $103.87 in the morning. In the 52-week period, the stock has ranged between $66.59 and $117.35 per share. The company traditionally operates in two segments, Diabetes and Obesity care, and Biopharm. The company is also in collaboration with Lund University and Bluebird, Inc to develop treatments for Parkinson's disease and genetic editing of humans.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.